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ABSTRACT
Genomic biobank research has experienced exponential growth in recent
years. It represents a real opportunity to remedy global health inequity
that has seen limited investment in diseases affecting populations from
low- and middle-income countries. Previous research in Africa was limited
to so-called parachute research, whereby samples were taken from local
populations for use in high-income countries with no local oversight or use
of the sample. These exploitative practices must be guarded against, but
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the current regulation of genomic research in Africa adopts a precautionary
approach that at times is restrictive in nature. We argue that the regulation
andoversight of genomicbiobank research should guard against exploitative
research, but in a manner that promotes reciprocal benefit and not restric-
tive research practices. To achieve this, there must be a rebalancing of the
regulatory tilt.
KEYWORDS: regulation, ethics, genomics, biobank, Africa, reciprocity
I. INTRODUCTION
Genomic biobank research, that is biobanking with the aim of fostering genomic
research, has brought about a change in our approach to medical research. In such
research, biological samples and biological data (collectively here referred to as bio-
logical materials) are collected, stored, and potentially re-used to advance genomic
research. These biological materials can easily be shared and moved across borders to
be re-used by researchers who were not originally involved in their collection. The rise
of genomic biobank research has been accompanied by a broader science policy shift
toward ‘open science’ that advocates the wide sharing of samples and data.
The ease with which biological materials can now be stored, transported across
borders, used and re-used has required a re-examination of long-held ethical princi-
ples. In particular, the ‘one-study, one informed consent’ paradigm is unsuitable in a
realm, where the sharing or reuse of biological material is not only encouraged but
also may be a condition of funding.1 Requiring that every participant is re-contacted
and re-consented each time the materials are to be re-used is burdensome and could
potentially lead to the waste of a valuable resource. In response to this, there has been
a growing acceptance internationally of broad consent, a consenting model through
which a participant donates their biological materials for future research use, subject
to further oversight by a research ethics committee (REC) or data access committee.2
Furthermore, there is growing recognition that the anonymization of biological mate-
rials may not be possible and the confidentially and privacy of the participant can no
longer be guaranteed.3
Genomic biobank research is often transnational research that involves international
collaborations and as a result, regulation of this research is increasingly complex. The
regulation of genomic biobank research is polycentric in nature and often involves
national and international actors and instruments, and rules and policies, which have
been developed in an uncoordinated manner.4 At the national level, this can include
1 David Secko, Nina Preto, SimonNiemeyer,Michael Burgess, Informed Consent in Biobank Research: A Deliber-
ative Approach to the Debate, 68 Soc Sci Med. 781, 782 (2009).
2 SeeChristine Grady, Lisa Eckstein, Ben Berkman, Dan Brock, Robert Cook-Deegan, Stephanie M. Fullerton,
Hank Greely, Mats G. Hansson, Sara Hull, Scott Kim, Bernie Lo, Rebecca Pentz, Laura Rodriguez, Carol
Weil, Benjamin S. Wilfond, David Wendler, Broad Consent for Research with Biological Samples: Workshop
Conclusions, 15 AJOB. 34–42 (2015). Paulina Tindana, Jantina De Vries, Broad Consent for Genomic Research
and Biobanking: Perspectives from Low- and Middle-Income Countries, 17 Annu Rev Genomics Hum Genet. 1
(2016).
3 Jeantine Lunshof, Ruth Chadwick, George M. Church,Hippocrates Revisited? Old Ideals and New Realities, 2
GenomicMed. 1,3 (2008).
4 JANE KAYE, SUSAN GIBBONS, CATHERINE HEENEY, ANDREW SMART, GOVERNING
BIOBANKS: UNDERSTANDING THE INTERPLAY BETWEEN LAW AND PRACTICE, 318
(2012).
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legislation, regulations, codes of conduct, and local RECpolicies. Added to thismay be
requirements set by international funders, legally enforceable international regulations
and treaties, professional codes of conduct, and consortia policies.5 These policies are
often in conflict, challenging collaboration, and the regulatory oversight of genomic
biobank research.
These issues have come to the fore in Africa in recent years where genomic research
has seen considerable development, fuelled in part through international collaborative
projects such as HapMap,6 MalariaGEN,7 H3Africa8, and B3Africa.9 The hope is that
the expansion of genomic research to the African continent could begin to remedy the
underrepresentation of Africans in international genomics research databases.10 This
expansion has led to increased personnel and infrastructural capacity for the research
on the continent. Yet there are challenges in governing the collection, storage, use, and
re-use of biologicalmaterials.11 The experiences in developing regulations for genomic
biobank research in high-income countries (HICs) can guide policy development in
Africa, but regulations developed elsewhere cannot simply be adopted and applied in
the African context. To do so would ignore the inequitable and sometimes exploitative
character of research collaborations with African countries in the past. It would also
fail to consider the different values that permeate African societies and that underpin
genomic biobank research on the continent. Thus, while in many HICs the challenge
for genomic biobank governance is to promote open science while respecting and pro-
tecting research participants, in Africa there is a need to develop and revise regulations,
so that they guard against exploitation, while fostering science that has the potential to
help remedy health inequity.12
The purpose of this paper is to identify key benchmarks, which are particularly
important in the regulation of genomic biobank research in Africa. It will begin by
critically reflecting on the current regulations before arguing that the regulations must
5 For example, see Council of Europe Convention for the Protection of Human Rights and Dignity of the Human
Being with Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
(Oviedo Convention) (1997); Council of Europe Convention for the protection of individuals with regard to the
processing of personal data 1980 (revised 2018);WorldMedical AssociationDeclaration of Helsinki; UNESCO
Universal Declaration on the Human Genome and Human Rights (1997). Ciara Staunton, Santa Slokenberga,
Deborah Mascalzoni, The GDPR and the Research Exemption: Considerations on the Necessary Safeguards for
Research Biobanks. 27 Eur J HumGen. 1159, 1162–1163 (2019).
6 International HapMapConsortium, Integrating Common and Rare Genetic Variation in Diverse Human Popula-
tions, 467Nature. 52–8 (2010).
7 The MalariaGEN Consortium, A Global Network for Investigating the Genomic Epidemiology of Malaria, 456
Nature. 732–7 (2008).
8 H3Africa Consortium, Research Capacity. Enabling the Genomic Revolution in Africa, 344 Science. 1346–8
(2014).
9 B3Africa, Bridging Biobank and Biomedical Research Across Europe and Africa, http://www.b3africa.org/?
page_id=2 (accessed Dec. 6, 2018).
10 Alice Popejoy, Stephanie Fullerton,Genomics is Failing on Diversity, 538Nature 161.
11 Ciara Staunton, Keymanthri Moodley, Challenges in Biobank Governance in Sub-SaharanAfrica, 14 BMCMed
Ethics. 35 (2013).
12 AminuYakubu, PaulinaTindana,AliceMatimba, SyntiaMunung,KatherineLittler,Ciara Staunton, Jantina de
Vries,Model Framework for Governance of Genomic Research and Biobanking in Africa—A Content Description,
1 AAS Open Res. 13 (2018). Jantina de Vries, Paulina Tindana, Katherine Littler, Michele Ramsay, Charles
Rotimi, Akin Abayomi, Nicola Mulder, Bongani M. Mayosi, The H3Africa Policy Framework: Negotiating
Fairness in Genomics, 31 Trends in Genetics. 117, 117 (2015).
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be re-framed in light of historical exploitative research. Drawing on our collective
experience in the ethico-legal oversight of genomic biobank research in Africa and on
published empiricalwork on this topic, wewill outlinewhat procedural and substantive
norms should guide the development of regulations in this context, before outlining
additional benchmarks for good governance of genomic biobank research in Africa.
II. THEREGULATIONOFGENOMICBIOBANKRESEARCH INAFRICA:
CURRENTPERSPECTIVES
In governing genomic biobank research in Africa, a key factor that needs to be con-
sidered is that historically much research on the continent has been more or less
exploitative in nature. The starkest example of exploitation is so-called parachute or
helicopter research, whereby biological samples were collected in Africa and sent back
to laboratories in other HICs for use in research,13 precluding the possibility of local
oversight of the use of the samples. As a result researchers in Africa lost a valuable
resource that could be used to develop local scientific capacity and for research on dis-
eases, which are relevant to the local population. Furthermore, any intellectual property
rights from resultant technologies or patents were lost to the local community and the
local economy.This practice has stemmed from inequitable ‘collaborative’ research that
exploited both research participants and scientists in Africa. Unsurprisingly, African
researchers can at times mistrust their international collaborators.14
This history of research on the continent makes it essential that the regulation
of genomic research in Africa guards against such practices and fosters a sense of
trustworthiness. Empirical research and engagement with stakeholders on this topic
demonstrates that participants do want to contribute to genomic biobank research
in Africa. Participants have expressed an appreciation of possible research benefits
and a desire that their contribution to science will benefit others.15 The regulation
of genomic biobank research in Africa should respect these motivations and enable
the research while also ensuring that they benefit African research participants and
research. Thus, we argue that genomic biobank regulations in Africa should enable
beneficial (non-exploitative research) in Africa.
There has been increasing attention on the governance issues affecting genomic
biobank research in Africa. In recent years, a number of studies have analyzed the
national ethics frameworks and regulations on genomic biobank research on the
African continent.16 The current national regulatory approaches can broadly be
13 Billie-Jo Hardy, Beatrice Seguin, Raj Ramesar, Peter A. Singer, Abdallah S. Daar, South Africa: From Species
Cradle to Genomic Applications, Nat Rev Gen. S19, S.20 (2008).
14 SeeROGERSCARLINCHENNELLS,EQUITABLEACCESSTOHUMANBIOLOGICALRESOURCES
IN DEVELOPING COUNTRIES: BENEFIT SHARINGWITHOUT UNDUE INDUCEMENT (2016).
Syntia Munung, Bongani M. Mayosi, Jantina de Vries, Genomics Research in Africa and its Impact on Global
Health: Insights from African Researchers, E12Genomic Med Global Health. doi:10.1017/gheg.2018.3 (2018).
15 Michael Igbe, Clement Adebamowo, Qualitative Study of Knowledge and Attitudes to Biobanking Among Lay
Persons in Nigeria, 13 BMC Medical Ethics. 27 (2012). Gerrit van Schalkwyk, Jantina de Vries, Keymanthri
Moodley, “It’s for a Good Cause, Isn’t it?”—Exploring Views of South African TB Research Participants on Sample
Storage and Re-use, 13 BMCMedical Ethics. 19 (2012). Keymanthri Moodley, Nomathemba Sibanda, Kelsey
February, Theresa Rossouw, “It’s my Blood”: Ethical Complexities in the Use, Storage and Export of Biological
Samples: Perspectives from South African Research Participants, 15 BMCMed Ethics. 4 (2014).
16 Ciara Staunton, Keymanthri Moodley,Challenges in Biobank Governance in Sub-SaharanAfrica, 14 BMCMed
Ethics. 35 (2013). Jantina de Vries, Syntia NchangwiMunung, AliceMatimba, SherylMcCurdy, Odile Ouwe
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divided into three categories: jurisdictions where no regulations exist; jurisdictions
that have regulations that are so specific that they quickly become outdated as the
technology develops; and jurisdictions that have some regulations, but they are lacking
certain key components.
In the first category where no regulations exist, De Vries et al. identified national
regulatory frameworks for only 22 countries, despite the study attempting to source the
regulations in all African jurisdictions. It is quite possible that the other countries—
which would be more than 30—have no official national or local ethics guidance for
health research. A national governance system should provide certainty and account-
ability in the legal and ethical conduct of research, and a lack of national guidelines or
regulations is problematic as it is unclearwhat rules andprocedures govern the research.
Arbitrarydecisionswill bemadeonan adhocbasis by a localRECand it is unlikely there
will be consistency of approach. It alsomakes it unclear what procedures, if any, are put
in place to guard against exploitative research and research practices.
Juxtaposedwith these jurisdictions are the second category of African countries that
have specific and detailed provisions on genomic and biobank research. This includes
Malawi, Zambia, Ethiopia, Nigerian, Rwanda, and South Africa.17 While regulating
genomic biobank research is important, in these cases, the regulations are often unsatis-
factory, and at times are so specific that they are quickly outdated as technology devel-
ops. This has occurred in Malawi and Zambia, where the regulations are particularly
restrictive for genomic research. While there have been calls for specific regulations
pertaining to genomic biobank research,18 theremust be someflexibility and reflexivity
of approach, so that the regulations can adapt to changes and developments in the
science.19
The majority of African jurisdictions fall into the third category, whereby genomic
biobank research is regulated within the general health research frameworks, although
only implicitly in some cases and more explicitly in others. Gaps identified in the De
Vries study were a lack of provisions on consent, ownership, reuse of samples, data
sharing, exportation/importation, and transfer of samples.20 Considering these are
MissiOukem-Boyer, Ciara Staunton, AminuYakubu, PaulinaTindana, TheH3AfricaConsortium, Regulation
of Genomic Biobank Research in Africa: A Content Analysis of Ethics Guidelines, Policies and Procedures from 22
African countries, 18 BMCMedEthics. 1 (2017). Francis Barchi,MadisonTLittle,National Ethics Guidance in
Sub-Saharan Africa on the Collection andUse of Human Biological Specimens: A Systematic Review, 17 BMCMed
Ethics. 64 (2016). M. Sathar, Ames Dhai, Laws, Regulations and Guidelines of Developed Countries, Developing
Countries in Africa, and BRICS Regions Pertaining to the Use of Human Biological Material (HBM) in Research,
5 S Afr J Bioethics and Law. 54–5 (2012). Annelize Gertruida Nienaber. Consent to and Authorisation of the
Export andUse ofHumanBiological Specimens for FutureResearch—Perspectives fromThreeAfricanCountries, 44
Comp IntLaw J SouthernAfrica. 225–54 (2011). Santa Slokenberga, JaneReichel, RachelNiringiye,Talishiea
Croxton, Carmen Swanepoel, June Okal, EUData Transfer Rules and African Legal Realities: Is Data Exchange
for Biobank Research Realistic? 9 Int Data Privacy Law. 30 (2019).
17 Pascalina Chanda-Kapata, Nathan Kapata, Albertina Ngomah Moraes, Gershom Chongwe, James Munthali,
Genomic Research in Zambia: Confronting the Ethics, Policy and Regulatory Frontiers in the 21st Century, 13
Health Res Policy Syst. 60 (2015).
18 Jantina de Vries, Akin Abayomi, Katherine Littler, Ebony Madden, Sheryl McCurdy, Odile Ouwe Missi
Oukem-Boyer, Janet Seeley, Ciara Staunton,GodfreyTangwa, PaulinaTindana, Jennifer Troyer,TheH3Africa
Working Group on Ethics. Addressing Ethical Issues in H3Africa Research—The Views of Research Ethics Commit-
tee Members, 9 HUGO. 1 (2015).
19 Graeme Laurie, Reflexive Governance in Biobanking: On the Value of Policy Led Approaches and the Need to
Recognize the Limits of Law, 130 HumGenet. (2011) 130:347–356.
20 Jantina de Vries, Syntia Nchangwi Munung, Alice Matimba, Sheryl McCurdy, Odile Ouwe Missi Oukem-
Boyer, Ciara Staunton, Aminu Yakubu, Paulina Tindana, The H3Africa Consortium, Regulation of Genomic
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issues that have an important bearing on genomics research, the absence in specificity
in the regulations on these topics is concerning. This suggests that, at the least, the
regulations fail to sufficiently prevent exploitative research.
A second important feature of these regulations is that they tend to adopt a precau-
tionary approach, which prescribes that in a state of scientific uncertainty, we should
avoid acting, or if we do act, we should act with extreme caution. Because in the case
of genomic biobanking, this principle most clearly manifests in the context of ethical
concerns, we will use the term the ethical precautionary approach.
In the African context, while it is imperative that regulations prevent exploitative
research and collaborations, this ethical precautionary approach at times has the net
effect of resulting in restrictive legislation. For example, in Zambia, the 2013 Health
Research Act specifically prohibits broad consent for future unspecified research as
section 47(2) states that biological materials cannot be withdrawn and used for ‘any
unspecified future health research activity or unspecified storage.’ Similarly in South
Africa, there have been concerns expressed that the use of broad consent for the sharing
of genomic data is not permissible under the Protection of Personal Information Act
2013.21
Precautionary measures in and of themselves are not a problem and ‘the State is
authorized to act in a precautionary way for the sake of the integrity of the Commu-
nity’.22 However, currently there is concern and some anecdotal evidence that overly
precautionarymeasures adopted to protect against exploitative research collaborations
is hampering research and efforts to develop capacity.23 In seeking to guard against
exploitative research and collaborations, the ethical precautionary approach could have
a considerable negative impact on the research generally.
III. SHIFTINGTHEREGULATORYTILT
The regulation of genomic biobank research should not overly restrict the research
or prevent collaborations. Rather the focus should be on guarding against exploitative
research and exploitative collaborations. By shifting our focus in this manner, we can
view genomic biobank research as something that is to be welcomed and important in
strengthening research capacity in Africa.24 Regulations thus should serve the goal of
supporting non-exploitative research and an important part of this is addressing many
of the gaps in the regulations that have been identified above. As such, we argue that
there should be a shift in the regulatory tilt.
The regulatory tilt refers to the extent to which regulations are permitting or pro-
hibiting research, and cases of ambiguity will be decided in favor of however the
Biobank Research in Africa: A Content Analysis of Ethics Guidelines, Policies and Procedures from 22 African
Countries, 18 BMCMed Ethics. 1 (2017).
21 Ciara Staunton,Rachel Adams,Marietjie Botes, Edward S.Dove, LynHorn,Melodie Labuschaigne, Glaudina
Loots, Safia Mahomed, Jennifer Makuba, Antonel Olckers, Michael S. Pepper, Anne Pope, Michele Ramsay,
Nora Ni Loideain, Jantina de Vries, Safeguarding the Future of Genomic Research in South Africa: Broad Consent
and the Protection of Personal Information Act 2013, 109 South AfricanMed J. 468 (2019).
22 ROGER BROWNSWORD, RIGHTS, REGULATION AND THE TECHNOLOGICAL REVOLUTION
451 (2008).
23 See below the section on stakeholder engagement.
24 AmbroiseWonkam, Bongani Moyasi,Genomic Medicine in Africa: Promise, Problems and Prospects, 6 Genome
Med. 11 (2014).
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law is tilting.25 Regulations that fall into the second category can be described as
tilting toward restriction. In other words, they tend to prohibit or restrict the research.
Jurisdictions falling into category one or three described above lack a clear tilt due to
the gaps or non-existence of regulatory structures.
It is submitted that a restrictive regulatory tilt is both a disservice to science inAfrica
and to efforts to rebalance global health inequity as it prevents the development of the
research.The regulatory tilt for genomicbiobank research inAfrica shouldbe re-framed
in favor of permitting non-exploitative genomic biobank research and collaborations.
Such a nuanced approach encourages the research and its allied benefits, but considers
mechanisms other than restrictive policies to prevent exploitative research and collab-
orations. To achieve this there must be a shift in the values underpinning the research
and this conversation has already begun.
The legacy of exploitative research is not unique to the African continent, and has
occurred in many resource-limited settings. In response, there has been a growth in
guidelines and codes to promote research in these settings, while guarding against
exploitative behavior. The Global Code of Conduct for Research in Resource Poor Set-
tings,26 developed by the EU funded TRUST project and now applies to all EU funded
research,27 puts the values of fairness, respect, care, and honesty at the heart of any
collaborative research betweenHICs and low- andmiddle-income countries (LMICs).
These values are echoed in guidelines developed by indigenous researchers in the
United States. The Guiding Principles for Engaging in Research with Native American
Communities focus on the following principles: research should be native-centered28;
respect; self-reflection and critical humility; authentic relationships; honor community
time frames; build on strengths; co-learning and ownership; continual dialog; trans-
parency and accountability; integrity; community relevance.29 The Guidelines for Eth-
ical Research in Australian Indigenous Studies have 14 principles that are grouped under
the broad categories of rights, respect, and recognition; negotiation, consultation,
agreement, and mutual understanding; participation, collaboration, and partnership;
benefits, outcomes, and giving back; managing research: use, storage, and access; and
reporting and compliance.30
In the context of biobank research, a call for the global governance of biobanks by
Chen and Pang seeks to remedy the disparity in capacity and governance between
LMICs and HICs through the following key elements: respecting participants and
donors of biological samples, and protecting their privacy and confidentiality; inform-
ing participants and donors of potential risks through initial consultations; sharing
25 Roger Brownsword, Red Lights and Rogues: Regulating Human Genetics, in THE REGULATORY CHAL-
LENGE OF BIOTECHOLOGY: HUMAN GENETICS, FOOD AND PATENTS 45 (Hans Somsen ed.,
2007).
26 TRUST, Global Code of Conduct, http://www.globalcodeofconduct.org/wp-content/uploads/2018/05/
Global-Code-of-Conduct-Brochure.pdf (accessed Dec. 10, 2018).
27 Linda Nordling, Europe’s Biggest Research Fund Cracks Down on ‘Ethics Dumping,’ 14 Nature. 17, 17 (2018).
28 Native centeredmeaning that ‘native American communities and people are the driving force of the research.’
29 Guiding Principles for Engaging in Research with Native American Communities, https://hsc.unm.edu/
vision2020/common/docs/Guiding_Principles_Research_Native_Communities2012.pdf (accessed Dec.
10, 2018).
30 AIATSIS,Guidelines for Ethical Research in Australian Indigenous Studies, https://aiatsis.gov.au/sites/default/
files/docs/research-and-guides/ethics/GERAIS.pdf (accessed Dec. 10, 2018).
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samples, data and benefits in a fair, transparent and equitable manner; ensuring quality
and interoperability of samples and their associated data; improving public awareness,
trust and participation in biobanks; and defining the role of the private sector in the use
of knowledge derived from biobank operations.31
In theAfrican context, two pertinent documents reflect these changes in values. The
San Code of Research Ethics32 was developed in response to exploitative and discrimi-
natory research published inNature involving members of the San Community.33 The
Code focuses on respect, honesty, justice, and fairness, care and due process as key
values to be considered when engaging with the San community for research. More
specifically for genomic biobank research, theH3Africa Consortium embarked on a
3-year stakeholder engagement and developed the Ethics and Governance Framework
for Best Practice in Genomic Research and Biobanking in Africa.34 The Framework is
guided by the principles of solidarity or communal-based worldviews, fairness, equity,
and reciprocity.
Although other guidelines and codes of practices do exist for genomic biobank
research, these new guidelines and codes of conduct are informed by past injustices
and inequitable collaborations. They do not seek to limit collaborations, but to foster
equitable research for the benefit of the local populations. As such they align andhelp to
inform our regulatory tilt and the principles of solidarity, reciprocity, justice, and trust
that are so important in these documents can inform the development or revision of
regulations that are reflective of this proposed new regulatory tilt. In particular, they
can help to identify some procedural and substantive norms that should underpin the
regulation of genomic biobank research in Africa. We will now briefly consider each
in turn.
Looking first at solidarity, solidarity-based approaches to genomic biobank research
have gained prominence in some HICs. Prainsack and Buyx have argued that biobank
governance should be guided by solidarity alongside autonomy35 as such an approach
would more appropriately reflect altruistic motivations to participate. Prainsack and
Buyx argue that solidarity overlaps with other concepts such as charity, reciprocity,
altruism, or empathy, but for them, their definition of solidarity (in its simplest form)
is ‘manifestations of people’s willingness to carry costs (financial, social, emotional, or
otherwise) to assist others.’36
As discussed in the H3Africa Framework, solidarity is reflective of the communi-
tarian worldview prevalent in African societies. Such a worldview focuses on the inter-
31 Haidan Chen, Tikki Pang, A Call for Global Governance of Biobanks, 93 Bull WHO. 113, 117 (2015).
32 San Council, San Code of Research Ethics (2017), http://trust-project.eu/wp-content/uploads/2017/03/
San-Code-of-RESEARCH-Ethics-Booklet-final.pdf (accessed June 11, 2001).
33 Roger Chennells, Andries Steenkamp, ‘International Genomics Research Involving the San People’ in ETHICS
DUMPING 15 (Doris Schroeder, Julie Cook, Francois Hirsch, Solveig Fenet, Vasantha Muthuswamy eds.,
2018).
34 H3Africa, Ethics and Governance Framework for Best Practice in Genomic Research and Biobanking in
Africa, https://h3africa.org/9-news/361-framework-for-african-genomics-and-biobanking (accessed June
11, 2018). Aminu Yakubu, Paulina Tindana, Alice Matimba, Syntia Munung, Katherine Littler, Ciara
Staunton, Jantina de Vries,Model Framework for Governance of Genomic Research and Biobanking in Africa—A
Content Description, 1 AAS Open Res. 13 (2018).
35 Barbara Prainsack, Alena Buyx, A Solidarity Based-Approach to the Governance of Research Biobanks, 21 Med
Law Rev. 71–91 (2013).
36 Ibid, 75.
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connectedness of society, recognizing that individuals are shaped by their relations to
people around them, and emphasizes respectful andharmonious relationships between
individuals, and between individuals and their environment. However, this view of
solidarity places importance on ‘reciprocity, consultation, and accountability’ and is in
part informed by abuses of research in the past. There is some expectation that ‘the
community also contributes to the individual’s sustainable wellbeing.’37
This formulation of solidarity differs from that as outlined by Prainsack and Buyx.
It signifies that an individual is willing to be involved and donate a sample for some
communal benefit. This manifestation of solidarity would be supportive of broad
consent, but there must be accountability to ensure benefit. If we understand broad
consent as ‘consent for governance,’38 researchers must be accountable within this
governance framework. Indeed this is not unique to the African context and in other
resource limited settings, the importance of accountability in the relationship between
the research team and the community involved in genomic biobank research has been
highlighted.39 We thus consider accountability to be an essential component of the
governance of broad consent in Africa and this brings us to our first procedural norm:
procedural accountability.
As part of solidarity, the H3Africa Framework places emphasis on the importance
of consultation. Community engagement is increasingly recognized as a critical com-
ponent in the ethical conduct of health research, and this is particularly pertinent
in communitarian societies. However, it is not just the research itself that must be
informed by community engagement, but the regulations themselves. If we are to truly
foster non-exploitative research, we must be adequately informed about the different
ways in which participants have been exploited. As noted by James et al., ‘researchers
who have not been grounded in, or are dismissive of, the historical context that shape
values and beliefs . . . cannot adequately assess “risk” related to cultural harms as per-
ceived by . . . groups.’40 Equally, if research is to be for some communal benefit, there
must be an understanding of this benefit. Thus, the development of genomic biobank
regulations and the implementation of the research must be supported by community
engagement. We consider community engagement to be both a procedural and sub-
stantive norm.
Now turning to reciprocity, as discussed, the conceptualization of solidarity in
H3Africa puts emphasis on the importance of reciprocity and recognizes that ‘as much
as the individual contributes to the community, the community also contributes to
37 H3Africa, Ethics and Governance Framework for Best Practice in Genomic Research and Biobanking in
Africa, https://h3africa.org/9-news/361-framework-for-african-genomics-and-biobanking (accessed June
11, 2018).
38 Barbara A. Koenig,HaveWeAskedTooMuch of Consent? 44HastingsCentre Rep. 33 (2014). PaulinaTindana,
JantinaDeVries,BroadConsent forGenomicResearch andBiobanking: Perspectives fromLow- andMiddle-Income
Countries, 17 Annu Rev Genomics HumGenet., 375, 388 (2016).
39 Angela Beaton, Maui Hudson, Moe Milne, Ramari Viola Port, Khyla Russell, Barry Smith, Valmaine Toki,
Lynley Uerata, Phillip Wilcox, Karen Bartholomew, Helen Wihongi, Engaging Ma¯ori in Biobanking and
Genomic Research: AModel for Biobanks to Guide Culturally Informed Governance, Operational, and Community
Engagement Activities, 19 GenMed. 345, 348 (2017).
40 Rosalina James, Rebecca Tsosie, Puneet Sahota, Myra Parker, Denise Dillard, Ileen Sylvester, John Lewis,
Joseph Klejka, LeeAnna Muzquiz, Polly Olsen, Ron Whitener, Wylie Burke; for the Kiana Group, Exploring
Pathways to Trust: A Tribal Perspective on Data Sharing, 16 GenMed 820. 822 (2014).
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the individual’s sustainable wellbeing.’ Once again this is not unique to the African
context and there is evidence that some indigenous groups expect reciprocity as a
guiding value in genomic and biobanking research, which should be built into the
process of donation and sharing of biological materials.41 Reciprocal benefits can take
the form of capacity building, improvements to health, or employment opportunities
for community members. Reciprocity is important at both a national and local level.
Nationally, the regulations should be informed by reciprocity as a mechanism through
which exploitative research is avoided. Locally, reciprocity and possible reciprocal
benefits should be discussed as part of community engagement. As such, it informs
both procedural and substantive law.With regards to justice, there has been a historical
lack of fairness in the access and use of biological samples obtained in Africa. Past
research practices often saw the uni-directional flow of samples for use in other HICs,
thereby preventing their use by local researchers, but it also prevented local oversight
of the sample. To remedy this, the fair use of biological materials must be supported by
procedural and distributive justice throughout the research process. Procedural justice
is concerned with the fairness and transparency of decision-making processes and an
integral part of that is establishing local and national policies on the use of biological
materials that are informed by community engagement. Local and national oversight
can help to prevent or at least limit exploitative research practices and ensure that there
are transparent processes in decisions on the use of the materials. Having policies in
place can also promote certainty and transparency and legitimize decisions on the use
of the biological materials. As such procedural justice should be a procedural norm.
However, it must be recognized that these biological materials are a valuable resource
and there may be justified reasons (such as capacity building) to warrant putting some
limits on its access. In the context of data sharing, controlling data access is seen as
important in protecting the rights and interests of the parties involved in genomic
data sharing42 and the same would apply to biological samples themselves. Thus in
the development of substantive legislation and policies on genomic biobank research,
distributive justice should be a guiding norm.
Finally, empirical evidencehashighlighted the importanceof trust in the governance
and success of genomic biobank research. Participants must trust the biobank, they
must trust the researchers, and the work must be conducted in such a way that par-
ticipation is seen as a ‘trustworthy activity.’43 There has been the suggestion in many
LMICs that participants’ trust in research has been eroded and by implication, trust in
researchers, but there has also been a loss of trust experienced between researchers in
41 Angela Beaton, Maui Hudson, Moe Milne, Ramari Viola Port, Khyla Russell, Barry Smith, Valmaine Toki,
Lynley Uerata, Phillip Wilcox, Karen Bartholomew, Helen Wihongi, Engaging Ma¯ori in Biobanking and
Genomic Research: AModel for Biobanks to Guide Culturally Informed Governance, Operational, and Community
Engagement Activities, 19 Gen Med. 345, 347 (2017). Rosalina James, Rebecca Tsosie, Puneet Sahota, Myra
Parker, Denise Dillard, Ileen Sylvester, John Lewis, Joseph Klejka, LeeAnna Muzquiz, Polly Olsen, Ron
Whitener,Wylie Burke; for theKianaGroup,Exploring Pathways to Trust: ATribal Perspective onData Sharing,
16 GenMed. 820, 822 (2014).
42 Mahsa Shabani, Pascal Borry, YouWant the Right Amount of Oversight”: Interviews with Data Access Committee
Members and Experts on Genomic Data Access, 18 Genet Med. 892, 892 (2016).
43 SusanWallace, BarthaMaria Knoppers, The Role of P3G in Encouraging Public Trust in Biobanks in TRUST
IN BIOBANKING 189 (Peter Dabrock, Jochen Taupitz, Jens Ried eds., 2012).
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LMICs vis a vis researchers in HICs.44 Trust is important on different levels and each
mustbe addressed in thegovernance framework for genomicbiobanking inAfrica: trust
between the participant and the researcher to whom they are donating their sample
and data; trust between the participant and the institution in which the materials are
stored; participant trust in the governance framework; trust between the regulators
and those implementing the research; and trust between researchers in Africa and
other international collaborators. A governance system that is built upon regulations,
which are legitimate, reflective of local values, and ensure accountability supports the
development of trustworthy relationships. Trust reinforces the importance of proce-
dural accountability, but to fully understand and address these differing layers of trust,
there should be wide stakeholder engagement on these matters. As such we consider
stakeholder engagement to be our final procedural norm.
IV. BENCHMARKS FORGOODGOVERNANCE FORGENOMICBIOBANK
RESEARCH INAFRICA
In an effort to reduce bureaucracy and improve the regulatory process, discussion
often focuses on good governance and key features that should support governance
to improve regulation. Within the European Union, the 2001 Mandelkern Report
on Better Regulation, which forms the basis of better regulation within the EU, set
out seven key principles for better regulation: necessity, proportionality, subsidiarity,
transparency, accountability, accessibility, and simplicity.45 In the UK, the Better Reg-
ulationTaskForce identifiedproportionality, accountability, consistency, transparency,
and targeting as its principles of ‘Better Regulation.’46 Good governance and better
regulation is also a feature of many international organizations, including the OECD
which sees improved regulatory policy as one of the key tools that governments can
use to improve societal welfare.47 Good governance is also seen as one of the principles
and objectives of the African Union (AU)48 and transparency, accountability and
participatory democracy are seen as important features of good governance within the
AU.49 In the context of genomicbiobank research,O’Doherty et al.have identified resp-
resentativeness, accountability, transparency, reflective, and sustainability as necessary
44 Syntia Munung, Bongani M. Mayosi, Jantina de Vries, Genomics Research in Africa and its Impact on Global
Health: Insights from African Researchers, E12Genomic Med Global Health. doi: 10.1017/gheg.2018.3 (2018).
45 Mandelkern Report on Better Regulation (2001) i. For more on the EU’s Better Regulation Policy see Com-
mission communication Smart Regulation in the European Union COM (2010) 543. Communication from
the Commission to the Council, the European Parliament, the European Economic and Social Committee
and the Committee of the Regions, ‘A Strategic Review of Better Regulation in the European Union’ COM
(2006) 690 final, COM(2006) 691 final. Communication from theCommission to the European Parliament,
the Council, the European Economic and Social Committee and the Committee of the Regions—Second
strategic review of Better Regulation in the European Union COM (2008) 33 final, COM (2008) 35 final,
Communication from the Commission to the European Parliament, the Council, the European Economic
and Social Committee and the Committee of the Regions—Third strategic review of Better Regulation in the
EuropeanUnionCOM/2009/0015 final, Communication from the Commission—Action plan “Simplifying
and Improving the Regulatory Environment COM (2002) 0278 final.
46 Better Regulation Taskforce, Principles of Good Regulation (2007).
47 OCED, Better Regulation Practices Across the European Union (2019).
48 Constitutive Act of the African Union (2000).
49 African Union, African Charter on Democracy Elections and Governance (2007).
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conditions for biobank governance.50 Shabani et al. have identified objectivity, fairness,
transparency, and accountability as important in improving the governanceof accessing
genomic data.51
In developing and revising its governance of genomic biobank research, African
law makers should consider each of these principles. The Better Regulation principles
have also been used as the basis on which to analyze biobank regulations in the UK.52
However, so as to ensure that regulations support our proposed reframing of the
regulatory tilt, we consider that law makers in Africa should be particularly guided by
the procedural norms (procedural accountability, community engagement, reciprocity,
and stakeholder engagement) and substantive norms (community engagement, reci-
procity) that we have outlined. In the final section of this paper, we will outline how
these norms should be reflected in a governance framework through an identification
of certain benchmarks for good governance for genomic biobank research in Africa.
Thesebenchmarks are tobe considered tobe in addition to the aboveprinciples of good
governance and Better Regulation and are what we propose are particularly pertinent
in achieving this re-framed regulatory tilt.
A. Legislative framework
As discussed previously, it is thought that many jurisdictions in Africa do not have any
national regulations for genomic biobank research. Regulations can clearly outline the
rules andpolicies that govern the use and re-use of biologicalmaterials and importantly,
specify the conditions under which non-exploitative research and collaborations can
take place. The purpose of our re-framed regulatory tilt is to protect the participant
from exploitative research and equally protect the research from exploitative research
and collaborations. These regulations can thus limit the use and re-use of thematerials,
particularly if they are to achieve either of those stated aims. Regulations however
cannot only prevent exploitative research, but also encourage non-exploitative research
by putting some limits on the research, provided this is in the interests of capacity
building. For example, national regulations can mandate that the use of samples and
data require a local principal investigator, or that samples will only be used overseas if
accompanied by an African student.
It is less important whether jurisdictions enact specific regulations for genomic
biobank research or regulate it within existing regulations for health research. What is
essential is that there is a national legislative scheme in place and that it aligns with the
regulatory tilt. However, in developing general data protection regulations that seek to
regulate the use of all types of personal data, lawmakers in Africa must be mindful that
the use of data for health research and for genomic biobank research require sector-level
responses to fill the regulatory gaps left by general data protection regulations.53
50 Kieran C. O’Doherty, Michael M. Burgess, Kelly Edwards, Richard P. Gallagher, Alice K. Hawkins, Jane
Kaye, Veronica McCaffrey, David E. Winickoff, From Consent to Institutions: Designing Adaptive Governance
for Genomic Biobanks, 73 Soc Sci Med. 367, 369 (2011).
51 Masha Shabani, Stephanie Dyke, Yann Joly, Pascal Borry, Controlled Access under Review: Improving the
Governance of Genomic Data Access, 13 PLoS Biol. e1002339.
52 Jane Kaye, Susan Gibbons, Catherine Heeney, Michale Parker, Andrew Smart, Governing Biobanks: Under-
standing the Interplay Between Law and Practice (Hart Publishing, 2012).
53 For example, in South Africa, a Code of Conduct has been called for to provide guidance on the application
of the Protection of Personal Information Act 2013 for genomic research. Ciara Staunton, Rachel Adams,
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Stakeholder engagement will be key in informing the development of the content
and substantive elements of these regulations. At a minimum they should regulate for
consent for future use of samples and data; use, re-use, and exportation of samples and
data; oversight of the use and regulatory approval; capacity building; benefit sharing;
community engagement; sample ownership and custodianship; and data sharing. It is
of particular concern that it appears that many jurisdictions in Africa lack regulations
on data sharing and protection for genomic biobank research, and there are concerns
that institutions in Africa do not have robust frameworks in place to oversee the use of
genomic data.54 This could also make adhering to the strict provisions of international
regulations such as the EU General Data Protection Regulation (GDPR) that can
at times apply to researchers in Africa challenging, and may compromise the ability
of researchers in Africa to collaborate with European institutions as well as access
EU funding. Where data protection regulations do exist, they are quite similar to the
GDPR and may not be reflective of the context in which they operate.55 For example,
restrictions on access to data, or preferential treatment to local researchers for a certain
period to enable them to maximize the use of the materials, can develop capacity in
this area.56 Although this is contrary to international best practice and some funding
requirements, which puts emphasis on rapid release of data, the interests of science in
Africa may require putting short-term restrictions on the sharing of data.57
B. Stakeholder engagement
Internationally, there is growing recognition of the importance of stakeholder engage-
ment not only in research but also in the development of regulations. The OECD’s
2012 recommendations require engagement with stakeholders at all levels, both in
developing and reviewing regulations. Guidance on how this can be done is currently
being developed in its Best Practice Principles on Stakeholder Engagement.58 Central
also to the European Commission’s Better Regulation Agenda is the involvement of
stakeholders, and in particular EU citizens, in the design and evaluation of regulations.
Good governance is also partly determined by the extent to which the functions of the
Marietjie Botes, Edward S.Dove, LynHorn,Melodie Labuschaigne,GlaudinaLoots, SafiaMahomed, Jennifer
Makuba, Antonel Olckers, Michael S. Pepper, Anne Pope, Michele Ramsay, Nora Ni Loideain, Jantina de
Vries, Safeguarding the Future of Genomic Research in South Africa: Broad Consent and the Protection of Personal
Information Act 2013, 109 South AfricanMed J. 468 (2019).
54 Ciara Staunton, Rachel Adams, Akin Abayomi, Edward S Dove, Natalie Harriman, Lyn Horn, Melodie
Labuschaigne, Nicola Mulder, Antonel Olckers, Anne Pope, Carmen Swanopoel, Nora Ni Loideain, Jantina
de Vries, “Ethical and Practical Issues to Consider in the Governance of Data Sharing for Genomic and Human
Research Data in South Africa: A Meeting Report,” AAS Open Res. 2:15 (2019).
55 Ciara Staunton, Rachel Adams, Dominique Anderson, Tay Croxton, Dorcus Kamuya, Marienne Munene,
Carmen Swanepoel, ‘Protection of Personal Information Act 2013 and Data Protection for Health Research in
South Africa,’ Int Data Privacy Law J. (2019, forthcoming).
56 AminuYakubu, PaulinaTindana,AliceMatimba, SyntiaMunung,KatherineLittler,Ciara Staunton, Jantina de
Vries,Model Framework for Governance of Genomic Research and Biobanking in Africa—A Content Description,
1 AAS Open Res. 13 (2018).
57 Michael Parker, Dominic Kwiatkowski, The Ethics of Sustainable Genomic Research in Africa, 17 Genome Biol.
44 (2016).
58 OECD Public Consultation on the Draft OECD Best Practice Principles on Stakeholder Engagement in Regu-
latory Policy, http://www.oecd.org/gov/regulatory-policy/public-consultation-best-practice-principles-on-
stakeholder-engagement.htm (accessed Dec. 10, 2018).
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State reflect the values of the stakeholders.59 Seen in this way, effective governance is a
partnership between the State and the relevant stakeholders, with stakeholders having
an important role in both development and implementation of regulations.
In the context of biobanks, it has also been recommended that stakeholder engage-
ment be one of the benchmarks for good governance.60 Such engagement is necessary
as internationally very few jurisdictions have introduced regulations in response to
biobanks, leaving it to other stakeholders such as RECs, advisory boards, funders, and
consortia to develop norms and procedures for biobanks.61
In Africa, there are similarly a multitude of stakeholders involved in the governance
of genomic biobank research including RECs, national regulator bodies, international
consortia, and individual biobanks.62 In particular, the H3Africa Consortium directly
engaged with REC members and national regulators in the development of its Gov-
ernance Framework, and indirectly with other groups through dissemination of the
draft Framework through meetings, networks and informal discussions.63 Although
it is intended that this document be used to guide the development of governance
frameworks across the continent, national engagement is of particular importance for
two reasons.
First, there are regional and cultural differences across the continent. Notably in
early drafts of this framework, Ubuntu, which is a philosophy that focuses on the
interrelatedness of humans,was selected as its normative basis. It soonbecameapparent
that there was resistance as the term is seen as South African that has strong links
to the apartheid struggle in South Africa, and is thus not reflective of developments
elsewhereon the continent.64 Regulationsmust thusbe contextualized to theparticular
jurisdiction and this can be achieved in part through stakeholder engagement.
Second, those implementing the regulations should broadly support them, other-
wise there will be a considerable disconnect between the law in the books and the
law in action. It is irrelevant if the regulatory tilt is reframed if the implementation of
the law shifts back to a more precautionary approach. This is perhaps best exemplified
by the perception of broad consent in Africa. Globally, there has been a move toward
recognition of broad consent as an ethically acceptable model of consent for genomic
biobank research. The ease with which samples and data can be shared with relatively
minimal risk to participants required a rethink of specific informed consent for this
research. Broad consent has faced some resistance at a national level (such as Zambia
59 Sameen Siddiqia, Tayyeb I. Masuda, Sania Nishtarb, David H. Petersc, Belgacem Sabria, Khalif M. Bile,
Mohamed A. Jama, Framework for Assessing Governance of the Health System in Developing Countries: Gateway
to Good Governance, 90 Health Policy. 13, 13 (2009).
60 JANE KAYE, SUSAN GIBBONS, CATHERINE HEENEY, ANDREW SMART, GOVERNING
BIOBANKS: UNDERSTANDING THE INTERPLAY BETWEEN LAW AND PRACTICE, 316
(2012).
61 See Jane Kaye, From Single Biobanks to International Networks: Developing E-governance, 130 Hum Genet. 377
(2011).GraemeLaurie,ReflexiveGovernance in Biobanking:On the Value of Policy LedApproaches and theNeed
to Recognise the Limits of Law, 130 HumGenet. (2011) 130: 347–356.
62 Ciara Staunton, Paulina Tindana, Melany Hendricks, Keymanthri Moodley, Rules of Engagement: Perspectives
on stakeholder Engagement for Genomic Biobanking Research in South Africa, 19 BMCMed Ethics. 19 (2018).
63 Aminu Yakubu, Paulina Tindana, Alice Matimba, Syntia Munung, Katherine Littler, Ciara Staunton, Jantina
de Vries, Model Framework for Governance of Genomic Research and Biobanking in Africa—A Content
Description, 1 AASOpen Res. 13 (2018).
64 Ibid.
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where the use of broad consent is prohibited). However, where regulations do exists,
the majority of jurisdictions explicitly or implicitly permit broad consent.65
Despite this, our engagement with RECs on the continent as part of the H3Africa
Ethics and Regulatory Issues Working Group informed us that irrespective of the
existence of regulations permitting broad consent, they were often hesitant to approve
studies that sought to adopt broad consent as the consent model for genomic biobank
research.66 Similarly, engagement with research participants in Zambia has demon-
strated support for broad consent but specific consent is mandated by the Health
Research Act 2013.67 This points to a disconnect between the law in statute and
law in action and demonstrates the crucial importance of stakeholder engagement in
developing regulations for genomic biobank research in Africa.
Stakeholder engagement can reveal any concerns with draft regulations as well as
regulations that are in force, and help to ensure that the implementation of regulations
is in line with the intent of lawmakers. In this way, it can also legitimize the regulations.
Part of stakeholder engagement will involve engaging with communities, and this will
be considered in further detail below.
C. Institutional responsibility
Aligned with the development and reformulation of regulations, we must identify a
process for ensuring accountability. Similar to stakeholder engagement, accountability
and lines of accountability are key features of good governance.68 The challenge is who
should be the appropriate body that has responsibility for oversight of the research and
hold the relevant parties to account.
In identifying the appropriate body, it may be useful to unpack their responsibili-
ties. First, they will have responsibility for ensuring that the regulations are followed.
Second, they will have oversight of the use, re-use, sharing, and possible export of
samples. This will include overseeing access arrangements, intellectual property rights
and by implication, bearing responsibility for the use of samples and data in research
and perhaps the researchers using the sample. It is thus not just the use of the sample
and data that the body will have responsibility for, but also holding the users of the
resources to account and ensuring that the use and future use of the research is non-
exploitative and has reciprocal benefits.
65 Ciara Staunton, Keymanthri Moodley, Challenges in Biobank Governance in Sub-SaharanAfrica, 14 BMCMed
Ethics. 35 (2013). Jantina de Vries, Syntia NchangwiMunung, AliceMatimba, SherylMcCurdy, Odile Ouwe
Missi Oukem-Boyer, Ciara Staunton, Aminu Yakubu, Paulina Tindana; the H3Africa Consortium, Regulation
of Genomic Biobank Research in Africa: A Content Analysis of Ethics Guidelines, Policies and Procedures from 22
African Countries, 18 BMCMed Ethics. 1 (2017).
66 Jantina de Vries, Akin Abayomi, Katherine Littler, Ebony Madden, Sheryl McCurdy, Odile Ouwe Missi
Oukem-Boyer, Janet Seeley,Ciara Staunton,GodfreyTangwa, PaulinaTindana, JenniferTroyer,TheH3Africa
Working Group on Ethics. Addressing Ethical Issues in H3Africa Research—The Views of Research Ethics
Committee Members, 9 HUGO. 1 (2015).
67 Oliver Mweemba, John Musuku, Bongani M. Mayosi, Michael Parker, Rwamahe Rutakumwa, Janet Seeley,
Paulina Tindana, Jantina De Vries, Use of Broad Consent and Related Procedures in Genomics Research: Per-
spectives from Research Participants in the Genetics of Rheumatic Heart Disease (RHDGen) Study in a University
Teaching Hospital in Zambia, Global Bioethics. doi: 10.1080/11287462.2019.1592868 (2019).
68 See JohnGraham, Bruce Amos and Tim Plumptre, Principles for Good Governance in the 21st Century, https://
iog.ca/docs/2003_August_policybrief15.pdf (accessed Dec. 10, 2018).
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We have discussed the importance of trust in genomic biobank research and the
different layers of trust that a governance framework must support. In the African
context, Tindana et al. have described an entrustment model that supports broad
consent. In this model, participants consent to the use of their sample in research and
entrust researchers to use their sample wisely. It is then the institution to which the
researcher belongs that has the obligation to ensure that the sample is used responsibly
and to ‘reciprocate by providing tangible health benefits.’69 For the authors, this model
creates a moral responsibility that the sample is used wisely with reciprocal benefits.
Thus, the researcher and the institution cannot dowhatever theywant with the sample.
O’Neill notes that we cannot simply takematters on trust, but establish ‘robust systems
of accountability’70 and Tindana equally notes that such a model is only acceptable
where the institution has well-founded relationships of trust with the community
and it is supported by governance and accountability.71 We have already begun to
unpack certain benchmarks for this system of governance and note the importance of
accountability, but it brings us back to our problemof identifying the bodywith powers
of accountability and the system through which that accountability comes about.
A number of different legal approaches that would be supportive of such account-
ability have been discussed elsewhere.72 Winickoff and Winickoff have proposed the
idea of a charitable trust model, whereby an independent body manages the trust and
ensures its use in accordance with the wishes of the donors.73 Such an approach does
embody elements of the solidarity-based approaches as it embodies this notion of
‘gifting’ (one presumes) for the benefit of others. Through the charitable trust, there
will be independent oversight and accountability on the use and re-use of the sample.
However, in such a model, the focus tends to be on the wishes of the donor, which
is a much more autonomy-based understanding of solidarity that is not necessarily
reflective of African values.
A model that may be more closely aligned to that proposed by Tindana et al. is the
establishment of a fiduciary relationship between the institution and the participant.
A fiduciary relationship arises when one party is entrusted to act on behalf of the best
interests of another party, such as the doctor–patient relationship. The doctor has a
moral responsibility to act in the interests of the patient, with legal consequences if
the doctor does not fulfill their fiduciary duties. In this context, the researcher clearly
could not be the trustee, as a trustee or agent cannot act in conflict of interest of the
trustor or principal. Their primary obligation is to the research, and the best interests
69 PaulinaTindana, SassyMolyneux, SusanBull,Michael Parker, ‘It is an Entrustment’: BroadConsent forGenomic
Research and Biobanks in Sub-Saharan Africa, DevWorld Bioethics. doi: 10.1111/dewb.12178 (2017).
70 Oonora O’Neill, Accountability, Trust and Informed Consent in Medical Practice and Research, 4 ClinMed. 269,
269 (2004).
71 PaulinaTindana, SassyMolyneux, SusanBull,Michael Parker, ‘It is an Entrustment’: BroadConsent forGenomic
Research and Biobanks in Sub-Saharan Africa, DevWorld Bioethics. doi: 10.1111/dewb.12178 (2017).
72 Empirical research in the Ma¯ori context has stated that the different models should be discussed with
stakeholders. See Angela Beaton, Maui Hudson, Moe Milne, Ramari Viola Port, Khyla Russell, Barry Smith,
Valmaine Toki, Lynley Uerata, Phillip Wilcox, Karen Bartholomew, Helen Wihongi, Engaging Ma¯ori in
Biobanking and Genomic Research: AModel for Biobanks to Guide Culturally Informed Governance, Operational,
and Community Engagement Activities, 19 GenMed. 345, 347 (2017).
73 David Winickoff, Richard Winickoff, The Charitable Trust as a Model for Genomic Biobanks, 349 N Engl J.
1180, 1181 (2003).
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of the participant may at times be in conflict with the best interests of the research
itself. Following from the entrustment model, the institution is to have certain moral
responsibilities and as a corollary, has fiduciary duties to the participant.
One possible challenge to this fiduciary model is that it protects the duties owed
by the trustee (ie the institution) to the trustor (ie the participant). Thus, one could
argue that the institutionmust only protect or guard against any risks to the individual.
Viewed through this lens, the institution is responsible for protecting the interests of the
participant, which includes the responsible future use of the sample and data.However,
the duties must be understood in the broader context of the research and the solidarity
basis on which the samples were donated. The institution is thus also responsible
for protecting the interests of the community, in which the biological materials are
donated. Such a type of fiduciary relationship may work in the African context if the
materials are held on trust for the benefit of the community.
A third approach that is perhaps more suitable to the genomic biobank context, is
the corporate governance model that involves shareholders, directors, and a company.
Under this approach, shareholders invest in the company. They are not involved in the
day-to-day running of the company, but have the opportunity during the annual general
meeting (AGM) or extraordinary general meetings (EGM) to vote and contribute to
the strategic vision of the company. It is the directors who run the business, but they
do so on behalf of the shareholders. The directors do not have fiduciary duties to the
shareholders (except in specific circumstances), but rather to the company.Their duties
include acting in the best interests of the company, ensuring that there is no conflict
of interest, acting within the company’s constitution and exercising independent judg-
ment.74
Such a model could apply to the genomic biobank context with some adjustments.
The shareholderswill not be the collective participants, but rather the community from
which the participants come. Thus, it is irrelevant if some individuals contributedmore
samples than others; they do not get extra ‘votes.’ The donation is for the communal
benefit and it is thus the community to which the institution must feedback through
AGMS or EGMs. The ‘company’ is the genomic biobank. It must act in the interests of
that biobank to the extent that it must ensure that it has no conflicts of interest, exercise
judgment in the exercise of its functions and also act within the governance framework
of the genomic biobank. The best interests of the biobank must not be thought of as
meaning ‘the best interests of research.’ Rather, as the institution must act with the
shareholders in mind, the best interests of the biobank are to be seen as the use of the
biological materials that is for the benefit of the community.
The advantage of such a model is that there are clear lines of responsibility and
accountability. It describes the continued role that the participant community should
have and ensures that the use and re-use of the biological material is not self-regulated
by researchers. We propose that it is the institution that is hosting the biobank that
must have ultimate oversight. This is supportive of the entrustment model discussed
by Tindana, but also mirrors developments in the oversight of data protection. The
emerging data protection regulations in Africa do specify clear lines of accountability
74 For more on the fiduciary duties owed, see Frank H. Easterbrook, Daniel R. Fischel, Contract and Fiduciary
Duty, 36 J Law Economics. 425 (1993).
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with the research institution the body with overall responsibility.75 Entrusting institu-
tions with responsibility for samples and data ensures a muchmore coherent approach
to the governance of samples and data.
In our view, institutions will serve two key functions. First, they must implement
national regulations pertaining to genomic biobank research, and second, they must
develop institutional policies. These policies will further guide the implementation of
the research and will focus on the substantive rather than procedural elements of the
law. It is at the individual project level, where reciprocal benefit sharing arrangements
with the local community can be developed.
It is useful to refer to Schroeder who defines benefit sharing as:
“Benefit sharing is the action of giving a portion of advantages/profits derived from
the use of human genetic resources to the resource providers to achieve justice in
exchange,with aparticular emphasis on the clear provisionof benefits to thosewhomay
lack reasonable access to resulting healthcare products and services without providing
unethical inducements”.76
Benefit sharing is thus much wider than direct benefit to the participant, but can
include other benefits such as capacity building. Indeed it is this conceptualization
of benefit that underpins the principles on which H3Africa was developed77 and it is
reflective of solidarity-based approaches of this research.
The possible content of benefit sharing arrangements is thus considerable and insti-
tutions should not adopt a policy on the specifics of such an arrangement. Rather, they
should require that any research consider formalized benefit sharing with communities
that is supported by community engagement.
D. Community engagement
This brings us to the final benchmark for good governance: community engagement.
Community engagement is seen as a requirement for the ethical conduct of research
and is a key feature of international codes of conduct for health research.78 It is
particularly necessary in the context of genomic biobank research as the research
has implications for the family and community, as well as the individual. It can help
to address the complex ethical and social factors with genomic biobank research.79
Controversies surrounding the Havasupai Tribe and research involving members of
the San community in genomic research demonstrate the problems that can arise
when research is conducted without engaging members of the community.80 It is of
75 Ciara Staunton, Rachel Adams, Dominique Anderson, Tay Croxton, Dorcus Kamuya, Marienne Munene,
Carmen Swanepoel, ‘Protection of Personal Information Act 2013 and Data Protection for Health Research in
South Africa,’ Int Data Privacy Law J. (2020, forthcoming).
76 Doris Schroeder, Benefit Sharing: It’s Time for a Definition, 33 J Med Ethics. 205, 208 (2007).
77 Bege Dauda, Steven Joffe, The Benefit Sharing Vision of H3Africa, 18 DevWorld Bioethics. 165, 166 (2018).
78 Ezekiel J. Emanuel, David Wendler, Jack Killen, Christine Grady,What Makes Clinical Research in Developing
Countries Ethical? The Benchmarks of Ethical Research, 189 J Infec Diseases. 930 (2004). H3Africa, Ethics and
Governance Framework for Best Practice in Genomic Research and Biobanking in Africa, https://h3africa.org/9-
news/361-framework-for-african-genomics-and-biobanking (accessed June 11, 2018).
79 Amy A. Lemke, Joel T. Wu, Carol Waudby, Jill Pulley, Carol P. Somkin, Susan Brown Trinidad, Community
Engagement in Biobanking: Experiences from the eMERGENetwork, 6 Genomics Soc Policy. 35 (2010).
80 Roger Chennells, Andries Steenkamp, ‘International Genomics Research Involving the San People’
in ETHICS DUMPING 15 (Doris Schroeder, Julie Cook, Francois Hirsch, Solveig Fenet, Vasantha
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particular salience in the African context, where a communitarian ethos permeates
many societies. Decisions are often taken in consultation with the family and other
members of the community. In addition, the traditional political structures give clear
authority to the elders, tribal leaders, and chiefs. The approval of these community
leaders will often be required prior to the commencement of the research. Thus, as part
of the institutional oversight of the research, a community engagement strategy must
be required as part of the research protocol. This should be supported by national reg-
ulations and should mandate that community engagement is an essential component
of research, unless it is deemed to be unnecessary by a REC.
Community engagement should not however simply be seen as important in the
design of the research itself. If the governance of genomic biobank research is to be
sensitive to the context in which it operates,81 the development of institutional policies
must be informed by community engagement and the institutional oversight of the
research should include community representation. By being a part of the design and
implementation of governance frameworks, the community can become part of the
accountability measures. As part of these accountability measures, there should be
feedback of findings to the community, and where possible, the individual.
Ensuring community engagement in national policy and strongly encouraging feed-
back of findings must also be met with resources to support training and imple-
mentation. To do otherwise would only give lip-service to such measures. National
training for community engagement will be necessary, but in resource limited settings
requirements that a certain percentage of a grant be spent on community engagement
(unless waived by a REC), could help to alleviate some resource concerns.
V. CONCLUSION
The growth of genomic biobank research in Africa represents a real opportunity to
help remedy global health disparity and develop scientific research capacity on the
continent. Allied with this must be recognition of the exploitative research practices
of the past and a commitment to ensuring ethical research practices. Good governance
and oversight of the research can help ensure that exploitative research does not occur,
but thismust not result in precautionarybased approaches that result in restrictive regu-
lations. Rather, the focus should be on how best to remedy the problem (ie exploitative
research and exploitative collaborations) in a way that can promote genomic research
as a means to increase scientific knowledge and improve the health of the population,
but in a manner that results in reciprocal benefits.
As a first step in achieving this, there is a need to shift the regulatory tilt to guard
against such exploitative research and collaborations. Thus, the regulatory tilt is neither
generally permissive nor restrictive, but rather focuses on preventing such research.
By following our additional benchmarks of legislative framework, stakeholder engage-
ment, institutional responsibility and community engagement for good governance for
genomic biobank research in Africa, this can support law makers in Africa following
this re-framed regulatory tilt.
Muthuswamy eds., 2018).MichelleMello, LeslieWolf,TheHavasupai IndianTribe Case—Lessons for Research
Involving Stored Biologic Samples, 363 NEJM. 204 (2010).
81 Brian Salter,Mavis Jones,Biobanks and Bioethics the Politics of Legitimation, 12 J Eur Pub Pol. 710, 724 (2005).
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